問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Colorectal Surgery

Digestive System Department

更新時間：2024-06-13

陳周誠CHEN, CHOU-CHEN
  • Principal Investigator
  • Clinical Trial Experience (year)

  • ccchen407@yahoo.com

Recruiting Trial

5Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳周誠

List

8Cases

2020-03-31 - 2028-01-27

Phase II/III

Active
A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Guselkumab/placebo

Participate Sites
4Sites

Recruiting4Sites

2020-07-24 - 2020-11-06

Phase II

Completed
An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal

  • Condition/Disease

    anal canal

  • Test Drug

    BI 754091; BI 836880

Participate Sites
4Sites

Terminated4Sites

2018-03-01 - 2020-06-16

Phase II

Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    ABT-165

Participate Sites
3Sites

Terminated3Sites

2021-06-17 - 2021-12-31

Others

A Phase Ib/II Study of PEP503 (Radioenhancer) with Radiotherapy, in Combination with Concurrent Chemotherapy for Patients with Locally Advanced or Unresectable Rectal Cancer

  • Condition/Disease

    The pathological diagnosis is confirmed as rectal adenocarcinoma, T3~T4, N any, M0 .The distal boundary of the tumor to the anal opening must be less than or equal to 10 cm.

  • Test Drug

    PEP503

Participate Sites
3Sites

Recruiting3Sites

2021-12-01 - 2025-07-31

Phase III

A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

  • Condition/Disease

    Colorectal Cancer (CRC)

  • Test Drug

    AMG 510；Panitumumab

Participate Sites
6Sites

Recruiting6Sites

2011-03-15 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2020-12-01 - 2024-05-17

Phase III

A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)

  • Condition/Disease

    short bowel syndrome and intestinal failure

  • Test Drug

    apraglutide

Participate Sites
3Sites

Recruiting3Sites

2021-09-20 - 2027-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB